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Abstract  
Context:  Subclinical hypothyroidism (SCH) is a common condition 
that has been associated with ischemic heart disease (IHD) in some, 
but not all studies. This may be due to differences in study design and 
the characteristics of participants. 
Objective: To investigate whether age and gender influence IHD 
prevalence, incidence and mortality in people with SCH. 
Data Sources: Computerised (PubMed, EMBASE and Cochrane 
Library) and manual searches of the literature to May 2007, published 
in English. 
Study Selection: Epidemiologic studies that quantified thyroid status 
and IHD events in adults. 
Data Extraction: Two authors independently reviewed articles and 
abstracted data. Results were compared across two groups based on 
the minimum age of participants studied (less than 65 years and 65 
years or more).  
Data Synthesis: Fifteen studies were included for analysis with 2531 
SCH participants and 26491 euthyroid individuals. IHD incidence and 
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prevalence were higher in SCH subjects compared to euthyroid 
participants from studies including those less than 65 years but not 
studies of subjects aged more than 65 years [Odds Ratio (95% CI)]: 
1.57 (1.19 to 2.06) vs 1.01 (0.87 to 1.18) and 1.68 (1.27 to 2.23) vs 
1.02 (0.85 to 1.22), respectively. Cardiovascular/all-cause mortality 
was also elevated in participants from the less than 65 years studies 
but not from the studies of older people; OR 1.37 (1.04 to 1.79) vs 
0.85 (0.56 to 1.29). Prevalent IHD was higher in SCH participants of 
both genders, although this was statistically significant only in women.  
Conclusion: SCH is associated with increased IHD (both prevalence 
and incidence) and cardiovascular mortality only in subjects from 
younger populations. These data suggest that increased vascular risk 
may only be present in younger individuals with SCH. 
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Introduction 
Subclinical hypothyroidism (SCH), defined as an elevated serum 
thyroid stimulating hormone (TSH) level associated with serum thyroid 
hormone concentrations within the reference range, is found in 4-10% 
of individuals from Western populations (1-3). Several observational 
studies comparing the outcome of SCH individuals to euthyroid 
subjects have shown divergent results, and it has been debated for 
some time whether SCH is independently associated with ischemic 
heart disease (IHD) (4, 5). If the latter were true, this would be an 
important public health issue for the ageing population, in whom SCH 
is most prevalent (1). Differences in reported outcomes from 
investigations that have compared IHD and/or mortality in people with 
SCH to that of euthyroid controls are not surprising, given the varied 
design and settings of the studies. For example, some studies have 
studied only women (6); others only elderly people (7-12) and others 
have been conducted in diverse populations (13, 14). A recently 
published meta-analysis has concluded that SCH individuals are at an 
increased risk of IHD (15). However, that meta-analysis pooled data 
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from studies with several different designs, including case-control and 
cohort studies, and outcomes including prevalence, incidence and 
mortality; thus making inferences from datasets that were neither 
uniform nor entirely comparable. Furthermore, additional large and 
high quality studies assessing the association between SCH and IHD 
have since been published (8, 9, 12, 14, 16).  
 
There have been suggestions that age (7, 17) and gender (6, 13, 18) 
may have an impact on IHD risk in people with SCH, but no 
quantitative analysis has been performed to investigate this. The 
purpose of this study was to examine the influence of age and gender 
on IHD and mortality in SCH. We, therefore, conducted a systematic 
review and meta-analysis of prospective cross-sectional and 
longitudinal population-based studies assessing IHD and mortality in 
SCH with stratification by age and gender.  
 
Methods 
Study selection 
Inclusion criteria:  
1. Types of studies: Population-based cross-sectional or longitudinal 
cohort studies of community living adults. We defined population-
based studies as those that included participants from the community 
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after screening and whom were not institutionalized, clinic-based or 
known to have a thyroid disorder. We defined cohort studies as those 
that selected controls from the same source population as the case 
participants. Population-based studies (cross-sectional and 
longitudinal) minimize false positive results due to selection bias and 
population stratification. 
2. Types of participants: Only studies that included individuals with 
mild SCH (TSH levels < 10 mIU/L) were used for the analysis.  
3. Outcomes: Outcomes were IHD events (prevalent and incident) and 
cardiovascular mortality. IHD events were defined as those confirmed 
by self-report, medical records, standardized IHD questionnaires or 
investigations (including electrocardiographs and coronary 
angiograms). Cardiovascular mortality was defined as death due to 
IHD, cerebrovascular and peripheral vascular diseases confirmed by 
death certificates or autopsy after evaluation of medical records. When 
all-cause mortality was reported but not IHD or cardiovascular 
mortality, then all-cause mortality was included.  
 
Literature search criteria 
A search of PubMed, EMBASE and the Cochrane Library was conducted 
between June 2006 and May 2007, for all relevant articles in English 
published from inception till May 2007, using the Medical Subject 
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Heading terms “thyroid diseases” AND “cardiovascular diseases” 
limited to adult humans. Further studies were identified from 
references of searched articles and from personal collections of the 
authors (Figure 1).  
Evaluation of studies 
All studies that were collected were then evaluated against pre-
determined criteria to assess quality. The criteria were: 
1. Unselected community-dwelling adults without preset criteria 
(e.g. not from one primary care practice, or health fair, only men 
or women, or atomic-bomb survivors). 
2. Excluded people with conditions or treatments that could affect 
thyroid function or people with previously treated thyroid 
disease, in reporting IHD. 
3. The primary outcome investigated was the association of thyroid 
diseases with IHD events and/or mortality.   
4. Measured thyroid hormones along with TSH to diagnose SCH. 
5. Adjusted (multivariate) analysis for confounding variables. 
6. Validated events by confirming by more than one method. 
 
One point was allocated for each criteria and a total score calculated to 
provide an overview of overall quality (table 2). 
The recommendations of the Meta-analysis Of Observational Studies in 
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Epidemiology (MOOSE) Group for reporting meta-analysis of 
observational studies was used to standardize and report data from 
each included study (19). Any uncertainty about any item was 
deliberated and resolved by agreement between the authors. 
Data extraction  
Two investigators (Drs Razvi and Shakoor) both independently 
extracted outcome data from included studies, and differences were 
resolved by discussion. When risk estimates (either as odds or hazard 
ratios) were reported after adjustment for variables, then the most 
fully adjusted multivariate model was included for analysis. For cross-
sectional studies that reported only raw event data, unadjusted odds 
ratios were calculated. Authors of studies that had not reported data in 
a useable form for inclusion in the analysis were contacted. Details 
were received from two of the investigators (6, 10), and were directly 
extracted for the Whickham survey (20). Additional data was then 
included for analysis of incident IHD (6), prevalent IHD and all-cause 
mortality (10), and incident IHD and IHD-mortality (20) (Supplemental 
information table).  
Data for cardiovascular (circulatory) disease mortality was available 
from four studies (8, 9, 14, 21). In the other studies non-neoplastic 
disease mortality (13), or all-cause mortality (7, 10) was used to 
abstract data on fatal events. In studies where risk of events was 
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reported as hazard ratio (7-9, 13, 14, 20), this was included as odds 
ratio since the two are similar when the event rate is low (22). For one 
study (21) that reported risk as standardized mortality ratio, published 
odds ratios previously derived from raw data were used (15).  
Other data extracted for each group were: number of participants, age 
at baseline, number of men and women, length of follow-up for 
longitudinal studies, adjusted risk estimates for outcome data and type 
of adjustment factors. In those articles that reported outcomes from 
the same study-population (9, 11, 14, 23-31), the article that most 
closely matched our inclusion criteria was included. All available case 
data were analysed for every participant for whom the outcome was 
obtained (available case analysis) (32).  
 
Statistical analyses 
Because of substantial qualitative and quantitative heterogeneity 
across studies, all analyses were performed using the random effects 
model, since this assumes that all studies are heterogeneous and thus 
provides a more conservative risk estimate. Adjusted risk estimates of 
effect were calculated by the generic inverse variance method. IHD 
events (both prevalence and incidence) and mortality were expressed 
as odds ratios (OR). For studies that reported only unadjusted 
dichotomous outcome data, risk estimates were calculated by the 
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DerSimonian and Laird method (33). Heterogeneity was tested by the 
χ2 test for degree of significance (where p<0.1 was taken as being 
indicative of statistically significant heterogeneity) and I2 test for 
magnitude of the heterogeneity (a value greater than 50% being 
indicative of substantial heterogeneity). Each contributing study was 
weighted so that larger studies with more precise estimates 
contributed more to the pooled result than smaller studies. The 
statistical package Revman 4.2 (Nordic Cochrane Centre, Copenhagen, 
Denmark) was used for analyses and for generating figures. 
Publication bias was assessed by funnel plot, in which the odds ratio 
was plotted on a logarithmic scale against its standard error for each 
study. The term ‘significant’ refers to statistical significance throughout 
this manuscript. 
A priori, two subgroup analyses were planned. To test the hypotheses 
that age and gender have varying effects on cardiovascular disease in 
people with SCH, we analyzed data from population-based trials 
categorized by age, using the minimum age of participants recruited of 
less than 65 years or 65 years and greater, and also divided by 
gender. The age of 65 years was chosen since the majority of trials 
that recruited older people had used this cut off (8, 11, 12). Age-
stratified data on outcomes were not available for any study and 
analysis was therefore not performed. 
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Post hoc, further subgroup and sensitivity analyses were conducted 
based on individual quality criteria, the level of TSH (‘mild’ SCH with 
TSH< 10 mIU/L), length of follow-up, after exclusion of studies with 
unpublished data and those without multivariate adjustment.  
Results 
Selection and Characteristics of studies: 
The search criteria identified 2215 studies (Figure 1). Irrelevant 
articles (n=2133) were excluded after their title and abstracts were 
studied. Full-text of the remaining articles and their reference list were 
reviewed and assessed against the inclusion criteria (Appendix 2 for 
web only). Finally, 15 studies (9 longitudinal) were included in the 
meta-analyses for IHD and mortality (6-14, 16, 18, 20, 21, 27, 34). 
Fig 1 here.  
 
Qualitative analysis 
The characteristics of the studies included for meta-analysis are 
summarized in Table 1. The mean age of SCH participants (taking age 
at baseline in longitudinal studies) was 60 and 74 years in those 
studies including participants with a minimum age of less than 65 
years and those including only people aged 65 years or more, 
respectively. The studies were performed in different geographical 
areas including the United States, United Kingdom, the Netherlands, 
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Australia, Japan, Denmark and Germany. The sample sizes of 
participants with SCH ranged from 6 to 496 whereas euthyroid 
individuals ranged from 353 to 5538. Overall the studies were well 
powered, with eleven of fifteen containing data from more than 1000 
participants. The minimum age for inclusion in a study varied from 18 
to 85 years across different studies. Twelve studies recruited both men 
and women whereas two studies recruited exclusively from one gender 
(Table 1). The upper-limit of normal TSH concentration above which 
SCH was defined also varied from 2.8 to 6.0 mIU/L, as did the degree 
of thyroid failure, with a mean TSH ranging from 3.7 to 8.9 mIU/L in 
SCH groups. It is pertinent to point out that studies have been 
conducted across different time periods and thus different serum TSH 
assays have been used. For example, two older studies used a less 
sensitive TSH radio-immunoassay (13, 34), whereas the rest of the 
studies have used third-generation chemiluminescent TSH assays. In 
the longitudinal cohort studies, follow-up periods ranged from 4 to 20 
years.  
The quality parameters of the various studies are outlined in Table 2. 
The primary analysis was IHD events or mortality in all but two 
studies. In one study it was the relationship of thyroid dysfunction with 
socioeconomic status (12) whereas in another it was its relation with 
carotid intima-media thickness (27). The quality of outcome 
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measurements was good with the majority of studies using standard 
definitions of outcomes, although the instruments varied widely. Most 
studies validated outcomes by different means with twelve studies 
using two or more methods to confirm primary outcomes, and only 
two studies using exclusively participant-reported data to define 
outcomes (16, 27).  
Ten studies were designed to assess long-term outcomes of common 
diseases and not primarily to assess the associations of thyroid disease 
with ischemic heart disease or cardiovascular events (6-11, 13, 14, 16, 
27). However, four studies were designed with the primary intention to 
assess the relationship between thyroid diseases and cardiovascular 
events or mortality (18, 20, 21, 34). All studies characterized 
participant’s thyroid status based on a single measurement, thus a 
proportion of these individuals may have had transient TSH 
abnormality. Thus the majority of studies were comparable in having 
vascular events as the primary endpoint and using standard criteria to 
define thyroid status and outcome measurements.   
Table 1 here.  
Table 2 here.  
 
IHD prevalence in SCH: 
Twelve studies assessed the prevalence of IHD in SCH (n=2399) 
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compared to euthyroid (n=24868) people (6, 8-14, 16, 18, 27, 34). 
The mean age of subjects in the SCH group was 66 years compared to 
65 years in the euthyroid group, with 63% and 53% of women in each 
respective group. Meta-analysis, using data that had been adjusted for 
covariates, showed that prevalent IHD was higher in the SCH group 
[OR 1.23 (1.02 – 1.48), p=0.03]. However, there was modest 
evidence of statistical heterogeneity (Figure 2). Subgroup analysis by 
age showed that IHD was more prevalent in SCH individuals compared 
to euthyroid subjects in the studies that included people who were less 
than 65 years of age [OR of 1.57 (1.19 – 2.06), p=0.001] (6, 13, 14, 
16, 18, 27, 34). However, this was not found in studies that involved 
only subjects greater than 65 years of age [OR 1.01 (0.87 – 1.18), 
p=0.9] (8-12). The significant statistical heterogeneity found in the 
whole dataset, was not found when either of the two subgroups were 
analyzed separately (Fig 2). The relative background risk of prevalent 
IHD events was about three times higher in more than 65 years 
studies (2442/12624 = 0.19) than in less than 65 years studies 
(828/14643 = 0.06).  
Five studies reported prevalent IHD separately for women (n=4313) 
and men (n=3166) (6, 11, 13, 18, 34). Prevalent IHD was higher in 
SCH women vs euthyroid female participants [OR 1.71 (1.26 – 2.34), 
p<0.001] with no significant heterogeneity. Prevalent IHD was 
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elevated in SCH men compared to euthyroid males, to a similar degree 
as observed in SCH women, although there were fewer male 
participants and the difference was not significant [OR of 1.66 (0.71 – 
3.88), p=0.24] (Figure 5). IHD events were twice as prevalent in men 
(308/3142 = 0.1) than in women (230/4248 = 0.05).  
Fig 2 here.  
Incidence of IHD in SCH: 
Meta-analysis was performed using data from 5 longitudinal studies 
that encompassed 954 SCH participants (67% women, mean age 65.2 
years) and 8,673 euthyroid individuals (57% women, mean age of 
62.4 years), followed for a median length of 8.6 years (6, 8, 9, 14, 
20). Overall, there was no difference in incident IHD in SCH individuals 
compared to euthyroid participants [OR of 1.27 (0.95 – 1.69), p=0.11] 
(Figure 3). However, there was evidence of substantial heterogeneity 
between these studies (Fig 3). When the 3 studies in the group 
including individuals less than 65 years (6, 14, 20) (n= 273 for SCH 
participants vs. 4443 for euthyroid) were analysed, the risk of incident 
IHD was significantly increased [OR of 1.68 (1.27 – 2.23), p<0.001]. 
This compares to an OR of 1.02 (0.85 – 1.22), p=0.83 in the two 
studies that included only individuals more than 65 years (8, 9) (n= 
834 for SCH participants vs. 5031 for euthyroid). There was no longer 
evidence for heterogeneity when studies from groups divided by age 
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were analyzed separately. The background risk of incident IHD events 
was similar in both groups. 
It was not meaningful to calculate incident IHD separately by gender 
since results were only available for 2 studies (6, 20).  
Fig 3 here. 
Cardiovascular mortality in SCH: 
Eight longitudinal studies assessed mortality in 1417 people with SCH 
and compared it to that of 13302 euthyroid participants (7-10, 13, 14, 
20, 21). The SCH group consisted of 64% women (mean age of 68 
yrs) compared to 53% women with a mean age of 65 yrs in the 
euthyroid participants. The median follow-up period was 10 years. 
Meta-analysis of the studies that assessed cardiovascular mortality (or 
all-cause mortality where cardiovascular-specific mortality was not 
available) showed that there was no overall increased risk in SCH 
individuals [OR of 1.09 (0.84 – 1.41), p=0.52]. There was, however, 
evidence of heterogeneity in these studies (Figure 4). Splitting the 
entire dataset by age, in studies including individuals aged less than 
65 years, SCH participants had an increased risk of cardiovascular 
mortality compared to euthyroid individuals [OR of 1.37 (1.04 – 1.79), 
p=0.02] (13, 14, 20, 21), whereas no such risk was evident in the 
studies with subjects more than 65 years only [OR of 0.85 (0.56 – 
1.29), p=0.44] (7-10). There was evidence of statistical heterogeneity 
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within the four studies in the more than 65 years group, which 
remained when a small study with wide confidence intervals (10) was 
excluded but disappeared completely when the study with the lowest 
age group (8) was excluded from analysis. No statistical heterogeneity 
was found amongst the less than 65 years studies (Fig. 4). 
The background risk of cardiovascular mortality was similar in both 
age group studies. When studies that reported cardiovascular mortality 
alone were considered (n=5) (8, 9, 14, 20, 21), there was no 
substantial change in the result obtained. 
We did not calculate gender-specific mortality differences since data 
were available from just two studies (13, 20). 
Fig 4 here. 
 
Sensitivity and post hoc subgroup analysis: 
Study quality: When studies stratified by minimum age (less than 65 
years and more than 65 years) were analyzed, based on individual 
quality scores, the results remained essentially unchanged, apart from 
IHD/all-cause mortality that was non-significantly raised in less than 
65 years group that excluded participants on medications affecting 
thyroid function (Table 3 for web). 
 
Different measure of effect size: There was no appreciable difference 
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in results of IHD outcomes when Relative Risk was used as a measure 
of risk ratio.    
 
Incident IHD and cardiovascular mortality in TSH up to 10 mIU/L 
group: There was no significant association between prevalent IHD and 
SCH in people with TSH less than 10 mIU/L in studies including 
individuals aged less than 65 years (14, 18, 34) with OR of 1.31 (0.92 
– 1.88), although incident IHD events were higher in this group (9, 14, 
20) with OR of 1.89 (1.38 – 2.57). These results were obtained from a 
relatively small number of participants (n=433 for SCH and 5359 for 
euthyroidism), and therefore need to be interpreted with caution. No 
analysis could be performed for prevalent and incident IHD events in 
the group of studies that included only subjects greater than 65 years 
due to non-availability of data, nor for mortality in SCH groups due to 
availability of data for only one study in each group (9, 20). 
 
Duration of follow-up: In the less than 65 years longitudinal studies 
group that had a follow-up period of more than 10 years, incident IHD 
was increased with an OR of 1.65 (1.24 – 2.20), with no heterogeneity 
between studies (8, 14, 20). Cardiovascular mortality was also 
increased with an OR of 1.37 (1.04 – 1.79) (8, 13, 14, 21). 
Interestingly, mortality was decreased in the more than 65 years 
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group studies that had follow-up data for less than 10 years [OR 0.67 
(0.48 – 0.92) (7, 9, 10). No analysis could be performed for less than 
65 years group studies with follow-up period of less than 10 years (6) 
or the more than 65 years studies group with follow-up period of more 
than 10 years (8) due to only one study being available for each, 
respectively. 
 
Publication bias: There was little evidence of publication bias in the 
studies reporting primary outcomes but this was difficult to interpret 
due to the small number of studies included. 
 
Unpublished data: We re-analyzed the data after excluding information 
from unpublished sources (See supplemental data). In the less than 65 
years studies, the results for prevalent and incident IHD remained 
unchanged but incident cardiovascular mortality became non-
significant [OR 1.51 (0.86 – 2.67), p=0.15] in the SCH group. 
 
Discussion 
This meta-analysis, which has involved only observational studies of 
unselected community-dwelling subjects, shows that subclinical 
hypothyroidism is associated with prevalent and incident IHD, as well 
as IHD mortality only in the studies that included participants less than 
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65 years of age. Importantly, studies stratified by age show little 
heterogeneity when either group is analyzed separately, but become 
significantly heterogeneous when the 2 age groups are combined. 
Thus, age appears to be a key variable in explaining the differences of 
the reported outcome of SCH in the various published studies. 
The striking effect of age on vascular risk that we observe in subjects 
with SCH may be explained in a variety of ways. Firstly, it is possible 
that at a younger age, SCH has a more severe pathophysiological 
effect, resulting in accelerated vascular disease perhaps through 
dyslipidaemia, endothelial dysfunction or a direct effect on the 
myocardium, in a proportion of susceptible individuals. As populations 
age, subjects who are relatively resistant to the adverse vascular 
effects of SCH may survive, leading to an attenuation of this effect in 
older age. Differential effects of other vascular risk factors during 
ageing are well-recognized, for instance being overweight does not 
appear to carry the same health implications in advanced age (35). An 
alternative explanation is that SCH is contributing equally to vascular 
risk at all ages, but in the more elderly cohorts there is a relatively 
larger component from conventional, non-SCH, vascular risk factors 
and that the effects of SCH are relatively masked by the larger 
contribution from other risk factors. The existing studies may simply 
not have enough power to detect a relatively small contribution to 
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vascular risk in this age group. Another possibility is that 
‘medicalization’ of people with SCH encourages them to report more 
IHD symptoms or access more investigation. The final possibility is 
that our findings represent a false positive result due to stochastic 
factors. We feel this latter is extremely unlikely, given that the effect 
of age is reproduced in different datasets and for the related outcomes 
of prevalent IHD, incident IHD and IHD mortality.  
The broad results obtained by this investigation are similar to three 
other meta-analyses that have examined the association of IHD with 
SCH (15, 36, 37). However, this meta-analysis has used stringent 
selection criteria, reduced bias by two authors independently 
extracting data, and included additional published and unpublished 
data. The age-dependent outcome of SCH has been commented on 
previously but never investigated systematically (Mariotti, Cooper, and 
Cooper). In this meta-analysis, we have explored various subgroups of 
study design and participant demographics to investigate the reason 
for the differences in results amongst the various original studies. This 
has led to robust confirmation of the hypothesis that the age of the 
cohort studied has an important bearing on the relative influence of 
SCH on IHD prevalence, incidence and outcome. From our analysis, 
the prevalence of IHD appears to be similar in both men and women 
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with SCH; however, this achieves statistical significance only in women 
probably due to a greater power to detect this association. 
 
Our meta-analysis of the literature has several limitations. It was 
limited to studies reported in English. We also excluded several case-
control, hospital-based and nursing home studies to limit bias. The 
greatest proviso is the heterogeneous nature of the different studies, 
which we have tried to reduce by using a random effects model and 
performing subgroup and sensitivity analyses. Still, it cannot be said 
with any degree of certainty that all variation between the different 
studies analyzed has been explained. Combining all the individual 
patient data from all the different studies and performing a priori 
subgroup analyses could go some way further towards this goal. The 
iodine status of participants in the different studies is unknown but all 
studies analyzed were carried out in iodine-replete areas. All studies 
classified participants into different thyroid status categories based on 
measurement of thyroid function at only one time point. Thus, a 
proportion of the participants may have had transient TSH elevation 
(for instance, following non-thyroidal illness) to account for abnormal 
results. The most extreme example of this was the Leiden 85-Plus 
study (7), where eleven of twenty-one elderly participants with SCH at 
baseline were euthyroid at three years. It should be emphasized that 
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the association, that we report, between SCH and IHD in younger 
individuals does not imply a causal relationship. This can best be 
investigated by prospective interventional trials.  
Currently, the indications for therapy of SCH in the general population 
are unclear. There is some evidence however, that adverse vascular 
risk factors may be ameliorated by L-thyroxine treatment (38-42). In 
contrast, the effect of L-thyroxine therapy on symptoms and well-
being in SCH remains ill defined (38, 41, 43-47). If therapy of SCH is 
to be considered on prognostic grounds, the finding that SCH is a more 
marked vascular risk factor in younger patients may have substantial 
implications.  Several individual studies have demonstrated that SCH 
in advanced age may not be associated with an adverse prognosis (7-
10). Thus, there may be an age or risk threshold, which remains to be 
defined, above which SCH should no longer be considered for 
treatment on prognostic grounds alone. Only well-powered prospective 
randomized studies with age - stratified groups, and vascular events 
as the primary endpoint rather than surrogate markers, will give clear 
answers to this complex question. 
In conclusion, this study shows that SCH is associated with increased 
IHD risk in younger age groups. Well-designed randomized controlled 
trials of treatment of SCH are needed to investigate if this risk can be 
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alleviated, but any such trial needs to take into account the age of the 
participants.  
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Figure 1. Flow chart outlining process of search criteria and study 
selection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies searched on 
PubMed, EMBASE and 
Cochrane Library using 
Medical Subject Heading 
database (n=2215) 
Full length articles 
reviewed (n=82)* 
Cross-sectional 
studies of SCH and 
IHD (n=6) 
Excluded (n=2133) 
Case-reports and 
letters (n=1123) 
Review articles 
(n=47) 
Not community-based 
populations (n=937) 
Intervention trials 
(n=26) 
 
Further excluded (n=67) 
No report of thyroid status (n=8) 
No report of outcomes (n=22) 
Multiple publications (n=10) 
Not population-based (n=11) 
Editorials/Letters/Reviews (n=16) 
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SCH = subclinical hypothyroidism, IHD = Ischemic heart disease. 
* Full list on Appendix 2 (for web only) 
Longitudinal 
studies of SCH 
and IHD or 
cardiovascular 
mortality (n=9) 
 26 
Table 1. Characteristics of cross-sectional and longitudinal population-based studies assessing ischemic 
heart disease (IHD) and mortality in people with subclinical hypothyroidism (SCH) compared with 
euthyroid individuals. 
Study, Year  
(Ref) 
Country Study 
design 
     n (at 
baseline) 
 
 
SCH    Eu 
Women 
% 
 
SCH      Eu 
Mean 
age in 
years 
SCH   Eu 
Normal 
TSH  
Range in 
mIU/L 
Mean TSH 
level in 
mIU/L 
SCH         Eu 
Outcomes measured Follow-
up 
period in 
years 
Tunbridge et al, 
1977 (34) 
Vanderpump et al, 
1996 (20) 
UK Cross-
sectional  
and  
Longitudinal 
132  2460 
 
 
76    1841 
74         51 
 
 
73         52  
52      47 
 
 
65      62 
 
0.3 – 6.0 
 
 
8.9          2.1 
Prevalent IHD. Incident 
IHD, all-cause and IHD 
mortality. 
 
 
20 
Hak et al, 2000 (6) Netherlands Cross-
sectional and 
Longitudinal 
124    931 
 
107    850 
100     100 69    69 0.4 – 4.0        N/A  Prevalent and incident 
IHD. 
 
4.6 
Parle et al, 2001 
(21) 
UK Longitudinal 94    1026 84         54 69      70 0.5 – 5.0       N/A  All-cause and circulatory 
mortality. 
10 
Gussekloo et al, 
2004 (7) 
Netherlands Cross-
sectional and 
Longitudinal 
 
30     472 
    N/A 85      85 0.3 – 4.8        N/A All-cause and CVD 
mortality. 
4 
Imaizumi et al, 
2004 (13) 
Japan Cross-
sectional and 
Longitudinal 
 
257  2293 
63         61 62      58 0.6 – 5.0 6.9          2.8 Prevalent IHD. 
All-cause and non-
neoplastic disease 
mortality. 
 
10 
Walsh et al, 2005 
(14) 
Australia Cross-
sectional and 
Longitudinal 
119  1906 69         48 58      49 0.4 – 4.0 6.3          1.4 Prevalent IHD. 
Incident IHD and IHD 
mortality. 
 
20 
Rodondi et al, 
2005 (9) 
USA Cross-
sectional and 
Longitudinal 
 
338  2392 
55         50 75      75 0.1 – 4.4       N/A Prevalent CVD and CHF. 
Incident IHD, all-cause 
and CVD mortality. 
 
 
4 
Van den Beld et al, 
2005 (10) 
Netherlands Cross-
sectional and 
Longitudinal 
6       353 0            0   N/A 0.4 – 4.3       N/A Prevalent IHD. 
 
All-cause mortality. 
 
 
4 
Cappola et al, 
2006 (8) 
USA Cross-
sectional and 
Longitudinal 
 
496  2639 
65         59 73      73 0.45 – 4.5 6.7          2.2 Prevalent IHD. 
Incident IHD, 
all-cause and IHD 
mortality. 
 
12.5 
Lindeman et al, 
2003 (11) 
USA Cross-
sectional 
112    643 66         44 76      74 0.6 – 4.6        N/A Prevalent IHD N/Ap 
Kvetny et al, 2004 
(18) 
Denmark Cross-
sectional 
249    963 58         45 42      43 0.6 – 2.8 3.7          1.7 Prevalent CVD N/Ap 
Volzke et al, 2004 
(27) 
Germany Cross-
sectional 
29    1745 69         45 59      62 0.3 – 3.0        N/A  Prevalent IHD N/Ap 
Wilson et al, 2006 
(12) 
UK Cross-
sectional 
168  5538 64         50 74      73 0.4 – 5.5 6.8          1.6 Prevalent vascular 
disease 
N/Ap 
Takashima et al, 
2007 (16) 
Japan Cross-
sectional 
377  3130 46         54 69      64 0.4 – 3.8 8.3          1.7  Prevalent IHD N/Ap 
Eu=Euthyroid, CVD = cardiovascular disease, CHF = congestive heart failure, N/A = not available, N/Ap = not applicable, USA = United States of America, UK 
= United Kingdom. 
 27 
Table 2. Quality of cross-sectional and longitudinal population-based studies assessing ischemic heart 
disease (IHD) and mortality in people with subclinical hypothyroidism (SCH) compared with euthyroid 
individuals. 
Study, 
Year (Ref) 
 Type of 
participants 
studied (1) 
Primary objective of 
main study (2) 
Participants 
on 
medications 
affecting 
thyroid 
function 
excluded? (3) 
Hormones 
measured to 
diagnose 
thyroid status 
(4) 
Instruments 
used to define 
outcomes (5) 
Completeness of 
observation  
(Persons in whom 
outcome 
ascertained/ 
Persons recruited) 
Covariates 
assessed (6) 
Total 
quality 
score 
(maximum 
possible of 
6) 
Tunbridge et 
al, 1974 (34) 
Vanderpump 
et al, 1995 
(20) 
Men and 
women ≥ 18 
years 
To assess IHD events 
and mortality in thyroid 
diseases. 
Yes TSH and TT4 Self-report, 
questionnaire 
ECGs, death 
certificates, 
autopsy reports 
and medical 
records. 
2779/2779 for 
prevalent IHD. 
 
2672/2779 for 
incident IHD and IHD 
mortality. 
Age and 
gender 
 
Age, gender, 
BMI, BP, DM, 
social status, 
smoking, TC, 
triglycerides 
6 
Hak et al, 
2000 (6) 
Community 
living women 
≥ 55 years 
To assess occurrence 
and risk factors for 
chronic diseases in 
men and women ≥ 55 
years 
Yes TSH  
FT4 only if TSH 
abnormal. 
Self-report, 
ECGs and 
medical records. 
994/1055 for prevalent 
IHD. 
 
1036/1055 for incident 
IHD.  
Age, BMI, TC, 
HDL, BP, 
smoking 
5 
Parle et al, 
2001 (21) 
Men and 
women ≥ 60 
years from 
one primary 
care practice. 
To assess mortality in 
thyroid diseases. 
Yes TSH  
FT4 only if TSH 
abnormal. 
Death 
certificates. 
1190/1191 for all-
cause and circulatory 
mortality. 
Age and 
gender 
4 
Gussekloo 
et al, 2001 
(7) 
Men and 
women ≥ 85 
years. 
Mortality Yes (in 
subgroup 
analysis) 
TSH and FT4 Self-report and 
ECG. 
558/558 for all-cause 
mortality. 
Gender, 
number of 
diseases, CRP, 
albumin 
6 
Imaizumi et 
al, 2001 
(13) 
Atomic bomb 
surviving 
adult men 
and women. 
To assess IHD events 
and mortality in SCH 
Yes TSH and FT4 Self-report, ECG 
and information 
from GPs.  
2550/2550 for 
prevalent IHD and 
non-neoplastic 
disease mortality.  
Age, systolic 
BP, BMI, TC, 
smoking, ESR 
and DM 
5 
Walsh et al, 
2005 (14) 
Men and 
women 17 – 
89 years. 
To assess risk factors 
for common diseases in 
a series of health 
surveys 
No (Self-
reported 
thyroid 
disease and 
goitre 
adjusted in 
analysis) 
TSH and FT4 Self-report, 
questionnaire, 
clinical records 
or ECG. 
2064/2108 for 
prevalent IHD. 
 
1890/2108 for 
incident IHD and CV 
mortality. 
Age, gender, 
BMI, BP, DM, 
social status, 
smoking, 
exercise, TC, 
triglycerides, 
self-reported 
thyroid 
disease, goitre 
5 
Rodondi et al, 
2005 (9) 
Men and 
women aged 
70 – 79 years 
To study change in 
body composition in 
older people and its 
association with other 
diseases 
No (for 
patients on 
thyroxine 
treatment, 
adjustment 
made in 
analysis).  
TSH 
FT4 only if TSH 
was ≤0.1 or ≥ 
7.0 mIU/L. 
Self-report, 
ECG, medical 
records and 
death 
certificates. 
2730/2730 for prevalent 
and incident IHD, and 
CV mortality. 
Age, gender, 
race, smoking, 
DM, prevalent 
CVD, health 
status, BP, TC, 
creatinine, 
education, 
income, 
thyroid 
hormone and 
ACE inhibitor 
use 
5 
 28 
Van den Beld 
et al, 2005 
(10) 
Independent 
men 73 - 94 
years. 
To assess 
determinants of 
chronic diseases in 
men and women 
Yes TSH, FT4 and FT3 Validated 
survey. 
386/403 for prevalent 
IHD. 
 
387/403 for all-cause 
mortality. 
Age 4 
Cappola et al, 
2006 (8) 
Men and 
women ≥ 65 
years 
To assess risk factors 
for IHD events and 
mortality  
Yes TSH  
FT4 only if TSH 
abnormal. 
Self-report, 
ECG, medical 
records, death 
certificates and 
autopsy reports. 
3233/3233 for prevalent 
and incident IHD, and CV 
mortality.  
Age, 
gender, 
race, 
smoking, 
DM, BMI, 
medication
s, lipids, 
CRP 
6 
Lindeman et 
al, 1999 
(11) 
Men and 
women ≥ 65 
years. 
To study health and 
health-related issues 
in equal number of 
elderly Hispanic and 
non-Hispanic white 
persons. 
No  TSH 
FT4 only if 
TSH>4.6 mIU/L 
Self-report and 
ECG. 
755/883 for prevalent 
IHD. 
None 3 
Kvetny et al, 
2000 (18) 
Men and 
women aged 
20 – 69 years 
from one 
primary care 
practice. 
To assess association 
of IHD with thyroid 
disease.  
Yes TSH  
FT4 only if TSH 
abnormal. 
Questionnaire 
and medical 
records. 
1212/1212 for prevalent 
CVD. 
None 4 
Volzke et al, 
2002 (27) 
Men and 
women aged 
45 – 79 years. 
Carotid intima-media 
thickness 
Yes TSH  
FT4 measured but 
not used in 
thyroid 
stratification 
Self-report. 2086/2086 for prevalent 
IHD. 
None 2 
Wilson et al, 
2006 (12) 
Men and 
women ≥ 65 
years from 20 
primary care 
practices. 
To assess association 
between 
socioeconomic status 
and thyroid disease. 
Yes TSH and FT4 Self-report and 
medical records. 
5872/5872 for prevalent 
vascular diseases. 
None 4 
Takashima 
et al, 2007 
(16) 
Men and 
women aged 
30 – 79 years. 
IHD events Yes TSH  
FT4 only if TSH 
abnormal. 
Self-report. 3607/3607 for prevalent 
IHD. 
None 
 
4 
 
SCH = subclinical hypothyroidism, IHD = ischemic heart disease, CVD = cardiovascular disease, CVA = cerebrovascular 
accident, PVD = peripheral vascular disease, CHF = congestive heart failure, TC = total cholesterol, LDLc = low density 
lipoprotein cholesterol, HDLc = high density lipoprotein cholesterol, BP = blood pressure, BMI = body mass index, DM = 
diabetes mellitus, FT4 = free thyroxine, ECG = electrocardiograph, GPs = General Practitioners, ESR = erythrocyte 
sedimentation rate, CRP = C reactive protein. 
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Figure 2. Forest plot of ischemic heart disease (IHD) prevalence in cross-sectional studies of subclinical 
hypothyroidism (SCH) and euthyroid controls. 
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Figure 3. Forest plot of ischemic heart disease (IHD) incidence in longitudinal studies in people with 
subclinical hypothyroidism (SCH) and euthyroid controls. 
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Figure 4. Forest plot of cardiovascular mortality in longitudinal studies of people with subclinical 
hypothyroidism (SCH) and euthyroid controls. 
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Figure 5. Forest plot of prevalent ischemic heart disease (IHD) in cross-sectional studies of people with 
subclinical hypothyroidism (SCH) and euthyroid controls divided by gender. (For web only) 
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Table 3. Outcomes for studies based on individual quality criteria* (for web only). 
 
               Prevalent IHD              Incident IHD        IHD/all-cause mortality 
Quality 
criteria 
Studies 
included in 
groups 
(Reference 
nos.)                
OR (95% CI) Studies 
included 
(Reference 
nos.)                
OR (95% CI) Studies included 
(Reference nos.)             
OR (95% CI) 
1 Less than 65 years 
(14, 16, 27, 34) 
65 years and more 
(8 - 12) 
1.55 (1.17 – 2.04) 
 
1.01 (0.87 – 1.18) 
Less than 65 years 
(14, 20) 
 
65 years and more (8, 
9) 
1.65 (1.24 – 2.20) 
 
 
1.02 (0.85 – 1.22) 
 
Less than 65 years (14, 
20) 
 
65 years and more (7 - 
10) 
1.67 (1.12 – 2.50) 
 
 
0.85 (0.56 – 1.29) 
2 Less than 65 years 
(6, 13, 16, 18, 27, 
34) 
65 years and more 
(8, 10, 12) 
1.48 (1.11 – 1.97) 
 
 
1.01 (0.82 – 1.26) 
Less than 65 years (6, 
20) 
 
65 years and more (8) 
1.58 (1.07 – 2.35) 
 
 
N/P 
Less than 65 years (13, 
20, 21) 
 
65 years and more (7, 
8, 10) 
1.32 (0.95 – 1.83) 
 
 
0.87 (0.51 – 1.45) 
 
3 Less than 65 years 
(6, 13, 14, 16, 18, 
34) 
65 years and more 
(8 – 10) 
1.59 (1.18 – 2.14) 
 
 
1.04 (0.88 – 1.23) 
Less than 65 years (6, 
14, 20) 
 
65 years and more (8, 
9) 
1.68 (1.27 – 2.23) 
 
 
1.02 (0.85 – 1.22) 
Less than 65 years (13, 
14, 20, 21) 
 
65 years and more (7 – 
10) 
1.37 (1.04 – 1.79) 
 
 
0.85 (0.56 – 1.29) 
4 Less than 65 years 
(6, 13, 14, 16, 18, 
34) 
65 years and more 
(8 – 12) 
1.59 (1.18 – 2.14) 
 
 
1.01 (0.87 – 1.18) 
Less than 65 years (6, 
14, 20) 
 
65 years and more (8, 
9) 
1.68 (1.27 – 2.23) 
 
 
1.02 (0.85 – 1.22) 
Less than 65 years (13, 
14, 20, 21) 
 
65 years and more (7 – 
10) 
1.37 (1.04 – 1.79) 
 
 
0.85 (0.56 – 1.29) 
5 Less than 65 years 
(6, 13, 14, 34) 
65 years and more 
(8, 9) 
1.84 (1.37 – 2.47) 
 
1.05 (0.88 – 1.24) 
Less than 65 years (6, 
14, 20) 
 
65 years and more (8, 
9)  
1.68 (1.27 – 2.23) 
 
 
1.02 (0.85 – 1.22) 
Less than 65 years (13, 
14, 20, 21) 
 
65 years and more (7 – 
9) 
1.37 (1.04 – 1.79) 
 
 
0.86 (0.56 – 1.34) 
6 Less than 65 years 
(6, 13, 14, 18, 34) 
65 years and more 
(8, 9, 11, 12) 
1.64 (1.16 – 2.34) 
 
1.01 (0.87 – 1.18) 
 
 
Less than 65 years (6, 
14, 20) 
 
65 years and more (8, 
9) 
1.68 (1.27 – 2.23) 
 
 
1.02 (0.85 – 1.22) 
Less than 65 years (13, 
14, 20) 
 
65 years and more (7 – 
9)  
1.43 (1.07 – 1.92) 
 
 
0.86 (0.56 – 1.34) 
* Results need to be interpreted with caution due to small number of trials in each group. 
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Quality criteria: 1. Unselected community-dwelling adults without preset criteria 2. Excluded people with conditions or 
treatments that could affect thyroid function or people with previously treated thyroid disease, in reporting IHD. 3. Association 
of thyroid diseases with IHD events and/or mortality was the primary outcome.  4. Measured thyroid hormones along with TSH 
to diagnose SCH. 5. Adjusted (multivariate) analysis for confounding variables. 6. Validated events by confirming by more than 
one method. N/P = Not possible to calculate pooled ratio due to only one study. IHD = Ischemic heart disease, CVD = 
cardiovascular disease. 
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Legend for Fig 1. Flow chart outlining process of search criteria and 
study selection. SCH – subclinical hypothyroidism, IHD – ischemic 
heart disease. 
 
 
Legend for Fig 2. Forest plot of ischemic heart disease (IHD) 
prevalence in cross-sectional studies of subclinical hypothyroidism 
(SCH) and euthyroid controls. Group 1 studies are those that included 
participants less than 65 years of age whereas Group 2 studies are 
those that only included participants 65 years or older. Although the 
overall prevalence of IHD was higher in SCH participants, the studies 
were heterogeneous, with an I2 of 44.9% (p=0.05). Dividing the 
studies according to age group substantially reduced the heterogeneity 
in both of the groups, and shows that the increased IHD prevalence is 
confined to the group 1 studies. 
 
Legend for Fig 3. Forest plot of ischemic heart disease (IHD) incidence 
in longitudinal studies of subclinical hypothyroidism (SCH) and 
euthyroid controls. Group 1 studies are those that included participants 
less than 65 years of age whereas Group 2 studies are those that only 
included participants 65 years or older. The overall incidence of IHD 
was not significantly higher in SCH participants but the studies were 
heterogeneous, with an I2 of 62.9% (p=0.03). Dividing the studies 
according to age group substantially reduced the heterogeneity in both 
of the groups, and shows that the increased IHD incidence is confined 
to the group 1 studies. 
 
 
Legend for Fig 4. Forest plot of cardiovascular mortality in longitudinal 
studies of people with subclinical hypothyroidism (SCH) and euthyroid 
controls. Group 1 studies are those that included participants less than 
65 years of age whereas Group 2 studies are those that only included 
participants 65 years or older. The overall incidence of mortality was 
not significantly higher in SCH participants but the studies were 
heterogeneous, with an I2 of 51.5% (p=0.04). Dividing the studies 
according to age group substantially reduced the heterogeneity of 
group 1, and shows that the increased IHD/cardiovascular mortality is 
confined to the group 1 studies. 
  
 
 
Legend for Fig 5. Forest plot of prevalent ischemic heart disease (IHD) 
in cross-sectional studies of people with subclinical hypothyroidism 
(SCH) and euthyroid controls divided by gender. (For web only) 
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Although the overall prevalence of IHD was higher in SCH participants 
compared to sex-matched euthyroid participants, the studies were 
heterogeneous, with an I2 of 47.6% (p=0.06). Dividing the studies 
according to gender substantially reduced the heterogeneity in the 
female group, and shows that the increased IHD prevalence is present 
in females with SCH, whereas it is non-significantly increased in men 
although these studies remained heterogeneous. 
 
 
 
Footnote for Table 1. Eu=Euthyroid, CVD = cardiovascular disease, 
CHF = congestive heart failure, N/A = not available, N/Ap = not 
applicable, USA = United States of America, UK = United Kingdom. 
 
Footnote for Table 2. SCH = subclinical hypothyroidism, IHD = 
ischemic heart disease, CVD = cardiovascular disease, CVA = 
cerebrovascular accident, PVD = peripheral vascular disease, CHF = 
congestive heart failure, TC = total cholesterol, LDLc = low density 
lipoprotein cholesterol, HDLc = high density lipoprotein cholesterol, BP 
= blood pressure, BMI = body mass index, DM = diabetes mellitus, 
FT4 = free thyroxine, ECG = electrocardiograph, GPs = General 
Practitioners, ESR = erythrocyte sedimentation rate, CRP = C reactive 
protein. 
 
 
Footnote for Table 3. * Results need to be interpreted with caution due to small 
number of trials in each group. 
Quality criteria: 1. Unselected community-dwelling adults without 
preset criteria 2. Excluded people with conditions or treatments that 
could affect thyroid function or people with previously treated thyroid 
disease, in reporting IHD. 3. Association of thyroid diseases with IHD 
events and/or mortality was the primary outcome.  4. Measured 
thyroid hormones along with TSH to diagnose SCH. 5. Adjusted 
(multivariate) analysis for confounding variables. 6. Validated events 
by confirming by more than one method. N/P = Not possible to 
calculate pooled ratio due to only one study. IHD = Ischemic heart 
disease, CVD = cardiovascular disease, OR = odds ratio. (For web 
only). 
 
 
 
